Biotech

All Articles

Merck stops stage 3 TIGIT test in lung cancer for impossibility

.Merck &amp Co.'s TIGIT system has actually endured another obstacle. Months after shuttering a peri...

After a challenging year, Exscientia folds up in to Recursion

.After a year specified by pipe cuts, the shift of its own CEO and discharges, Exscientia will merge...

Cullinan, after $25M package, restore bispecific to Port

.Cullinan Therapy was impressed sufficient along with Port BioMed's bispecific invulnerable reactor ...

A deeper examine Tough Biotech's Brutal 15

.In this particular week's episode of "The Best Line," we are actually diving right into Tough Biote...

Lilly encounters period 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's event commemorating the approval of Alzheimer...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of considerable leadership hirings, firings...

Lykos will definitely ask FDA to reexamine its own choice observing turndown of MDMA treatment for post-traumatic stress disorder

.Complying with an unsatisfactory presenting for Lykos Therapies' MDMA prospect for post-traumatic s...

AN 2 fifty percents roll call, ceases phase 3 trial after information disappoint

.AN2 Therapies is actually reassessing its own company in feedback to lackluster midphase informatio...

Merck pays out $700M for bispecific, spying autoimmune position as well as chance to challenge Amgen in cancer cells

.Merck &amp Co. is actually spending $700 million upfront to challenge Amgen in a blood cancer cells...

Gilead pays for J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences on the verge of an FDA choice for its own liver health condition drug se...